ABSTRACT Background: Impaired one-carbon metabolism is thought to be associated with the risk of neural tube defects (NTDs); however, the role of methylation in NTDs remains unclear. Long interspersed nucleotide element-1 (LINE-1) constitutes 17-25% of the human genome. LINE-1 hypomethylation correlates with global DNA methylation levels in cancerous cells, but limited information is available on LINE-1 methylation in NTDs. Objective: We determined whether LINE-1 methylation patterns were associated with neural tube development and the possible relations between DNA methylation and key maternal metabolites involved in folate-mediated one-carbon metabolism. Design: Global methylation, maternal plasma folic acid, vitamin B-12, and total homocysteine (tHcy) concentrations were assessed in 48 NTD and 49 control samples by immunoassay, and LINE-1 methylation levels were evaluated by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Results: Methylation levels of genomic DNA and LINE-1 decreased significantly in the neural tissue of NTD samples. The risk of NTDs increased with decreasing levels of LINE-1 methylation, with an odds ratio of 5.246 (95% CI: 1.519, 18.124; P = 0.009) for the lowest quartile (methylation level 57.94%) compared with the highest quartile (methylation level 60.94%). Compared with control subjects, case subjects had lower maternal plasma concentrations of vitamin B-12. Conclusions: Hypomethylation of LINE-1 and genomic DNA was associated with an increased risk of NTDs. Functional insufficiency of maternal plasma vitamin B-12 was associated with NTDs, although no significant correlation could be established between maternal folic acid, vitamin B, tHcy, and LINE-1 methylation.
INTRODUCTION
Neural tube defects (NTDs) are thought to be associated with genetic defects and environmental factors. Malnutrition in pregnancy is one of the risk factors for NTDs. Seminal work by Smithells et al (1) showed that the diet and postpartum blood of NTD-affected women were deficient in several micronutrients, particularly folate. Subsequent epidemiologic studies indicated that lower concentrations of folate and vitamin B-12 during pregnancy are related to an increased risk of NTDs (2) (3) (4) .
Intracellular folic acid and vitamin B-12 are key players in providing an adequate source of methyl groups for methylation of DNA and proteins, in addition to their involvement in purine and pyrimidine metabolism and, therefore, DNA synthesis. Several lines of experimental evidence suggest that impaired DNA methylation is an underlying mechanism of NTD formation (5) (6) (7) (8) (9) , and another study (10) illustrated that folic acid functions in preventing NTDs by partially reducing or reversing aberrant DNA methylation via the one-carbon metabolism pathway.
DNA methylation patterns are established early in embryonic development and can be influenced by malnutrition. Transposons and imprinted genes are 2 classes of elements within the human genome that have methylation patterns that are sensitive to malnutrition in early embryonic development (11) . Among those, long interspersed nucleotide element-1 (LINE-1) is a mammalian autonomous non-long-terminal repeat retrotransposon that constitutes '17-25% of the human genome with up to 600,000 copies per genome (12) . The expression of the LINE-1 retrotransposon is precisely regulated by epigenetic mechanisms, whereas activation of LINE-1-mediated retrotransposition can affect downstream gene expression genetically and epigenetically (13) . LINE-1 elements are normally silenced by hypermethylation except for a brief period of global demethylation in the early mammalian embryo (14, 15) . It was shown that the LINE-1 methylation level decreases in cancerous cells and correlates with global DNA methylation level (16) (17) (18) (19) . In addition, a recent study (20) suggested that lower folate intake would likely result in LINE-1 hypomethylation colon cancers, providing a potential link between the serum folate level, LINE-1 hypomethylation, and risk of colon cancer.
To explore the potential influence of DNA methylation on neural tube closure, we measured and compared the methylation levels of genomic DNA and LINE-1 elements in NTD samples and case control samples. Because disturbed one-carbon metabolism is known to be both an independent risk factor for NTDs and a key modulator of genomic methylation, a possible cor-relation between the methylation levels of LINE-1 and genomic DNA and the maternal plasma concentrations of folic acid, vitamin B-12, and total homocysteine (tHcy) was investigated.
SUBJECTS AND METHODS

Sample collection
Stillborn NTD case subjects were obtained from the Shanxi Province of Northern China from March 2004. Medical abortions were carried out in local county hospitals that diagnosed NTDs by B-ultrasound, and clinical information such as sex, gestation period, and the general development of the embryo were recorded in detail. A pathologic diagnosis of NTDs was completed by experienced pathologists according to the International Classification of Disease, Tenth Revision, codes Q00.0, Q05.9, and Q01.9 (http://apps.who.int/classifications/). Forty-eight case subjects were retained for analysis, including 27 subjects with cephalic malformations (22 subjects with anencephalus and 5 subjects with encephaloceles) and 21 subjects with spina bifida. The classification methods used in this study were based those devised by Cabaret et al in 2007 (21) . Forty-nine control subjects, who were aborted for nonmedical reasons, were also obtained from the Shanxi Province and selected according to sex and gestational week. Any fetuses displaying pathologic malformation or intrauterine growth retardation were excluded from the control group. The routine prenatal checkup and questionnaire and the autopsy report were completed for all NTD case and control subjects. All pregnancies lacked preconception folic acid supplementation. In addition, pregnancies that had been exposed to anti-folic acid or any known antimethylation medications were excluded from the study.
All samples for DNA extraction were stored at -20°C in local hospitals before shipping, on ice, to the study laboratories. Nervous tissue (brain tissue and residues of brain tissue) were obtained from test and control subjects.
Blood samples from pregnant women were collected just before abortion. Generally, 2 mL venous blood was collected into purple-top evacuated tubes (without anticoagulant; Becton Dickinson). Blood samples were immediately centrifuged at 2500 rpm for 10 min, and the separated plasma was aliquoted (without reducing agent) and stored at -20°C in local hospitals before shipping, on ice, to the study laboratories. Samples were not thawed until analysis. A total of 32 test samples and 36 control samples were tested.
The study was approved by the local ethics committee, and written informed consent was obtained from all participants or their parents. Information relating to all of the subjects used in the study is shown in Table 1 .
Biochemical analyses
Plasma folate and vitamin B-12 were measured by using a competitive receptor binding immunoassay (Chemiluminescent Immunoenzyme Assay Access Immunoassay system II; Beckman Coulter, Krefeld, Germany). The intraassay CV for folate and vitamin B-12 was 3.8-6.5% and 5-7%, respectively. tHcy was measured with a Hitachi Model 7170A automatic analyzer (Hitachi, Tokyo, Japan) with the homocysteine assay kit (JiuQiang Company, Beijing, China). The intraassay CV for tHcy was 2.6-4.0%.
DNA methylation analyses
DNA extraction
Genomic DNA was extracted from nervous tissues with the Blood and Tissue DNA Kit (QIAGEN, Dusseldorf, Germany) according to manufacturer's instructions. The concentration and purity of the DNA were determined by absorbance at 260 and 280 nm.
Global methylation analyses
Global DNA methylation was detected with the Methylamp Global DNA Methylation Quantification Ultra Kit (Epigentek, New York, NY). In this assay, the methylated fractions of DNA are recognized by an anti-5-methylcytosine antibody and quantified by using an enzyme-linked immunosorbent assay-like reaction. Polymerase chain reaction products and genomic DNA after DNA methylation enzyme (MSss.I) treatment (Promega, Madison, WI) were used as negative and positive controls, respectively. Triplicate tests were performed on each sample. Test and control samples were measured simultaneously to avoid systemic bias.
Bisulfite treatment
A total of 200 ng genomic DNA from each sample was bisulfite-treated with the Methylamp DNA Modification Kit (Epigentek). The quality of the bisulfite conversion was controlled by using PCR products that had no methyl group. Sequencing results confirmed that .96.6% of cytosine residues were converted. 
LINE-1 methylation analyses
The Sequenom MassARRAY platform (CapitalBio, Beijing, China) was used to perform the quantitative methylation analysis of LINE-1 (Gen-Bank accession number X58075). This system uses matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry in combination with RNA base-specific cleavage (MassCLEAVE). A detectable pattern is then analyzed for its methylation status. PCR primers were designed with Methprimer (http://epidesigner.com). For each reverse primer, an additional T7 promoter tag for in vivo transcription was added, as well as a 10-mer tag on the forward primer to adjust for melting temperature differences. We used the following primers on the basis of the reverse complemented strand of LINE-1 (5#-aggaagagagGTGTGAGGTGTTAGTG-TGTTTTGTT-3# and 3#-cagtaatacgactcactatagggagaaggctATA-TCCCACACCTAACTCAAAAAAT-5#) to amplify base pairs 335-767 of the LINE-1 promoter. In total, 11 CpG sites (which were divided into 8 CpG units) were examined in this area, except for the 10th CpG site that had no signal ( Figure 1 ). The spectra methylation ratios were generated by Epityper software version 1.0 (Sequenom, San Diego, CA).
To validate the results from the MassARRAY platform (Sequenom), 10 samples were picked at random, including 3 test and 7 control samples. The LINE-1 elements were amplified after bisulfite treatment by using primers designed to amplify base pairs 337-711 of LINE-1. PCR products were cloned into a cloning vector pMD-18 T (Takara, DaLian, China). Twenty clones were analyzed at random by automatic sequencing to determine the proportion of methylated (CpG) and unmethylated (TpG) sites.
Statistical analyses
Data were put into the EPI 3.1 Database (EpiData Association, Odense, Denmark) and analyzed with the SPSS-11.5 software package (McGraw-Hill Inc, New York, NY). All P values were 2-sided, and P , 0.05 was considered to be significant. Independent t tests were performed to evaluate the significance of any differences between test and control groups. One-factor analysis of variance was used to evaluate the difference between cephalic malformation, spina bifida, and control samples. A repeated-measures analysis was used to compare the results from MALDI-TOF mass spectrometry with those from bisulfite sequencing, and LINE-1 methylation profiles were plotted with Matlab7.0.4 software (The MathWorks, Natick, MA). Correlation analysis was performed by using bivariate correlations. Odds ratios (ORs), which were used to evaluate the incidence of NTDs relative to methylation levels, were calculated with a 95% CI. The adjusted ORs (AORs) were calculated by logistic regression.
RESULTS
DNA hypomethylation in NTDs
We compared the global methylation levels of NTD samples with that of control samples. As shown in Table 2 , the genomic DNA of NTD samples exhibited a significantly lower mean methylation level (5.01%) than control samples (5.95%) (P = 0.047). Global methylation varied between cephalic malformation, spina bifida, and control samples. Cephalic malformation samples had the lowest methylation level (4.79%) followed by spina bifida samples (5.26%) and control samples (5.95%).
It is known that LINE-1 methylation status is a good predictor of genome-wide methylation on the basis of cellular 5-methylcytosine. Therefore, we measured methylation levels of LINE-1 in nervous tissue from both NTD and control samples. With the use of primers designed to amplify a 432-base pair sequence (Figure 1 ), LINE-1 elements were amplified from 48 NTD and 49 control samples after bisulfite conversion of genomic DNA. The FIGURE 1. Schematic diagram of long interspersed nucleotide element-1 (LINE-1). LINE-1 transcript comprises a 5# untranslated region (5#-UTR) with internal promoter activity, 2 open reading frames (ORF1 and ORF2), and a 3#-UTR. The sequence shown represents a 432-base pair fragment (base pairs 335-767) in the 5#-UTR of LINE-1. Polymerase chain reaction primers were designed on the basis of the reverse complemented strand of this fragment. Numbers 1-12 refer to locations of the CpG site within the LINE-1 elements tested, and underlining highlights the CpG units that include more than one CpG site tested at the same time.
mean methylation levels were then compared by using Student's t test ( Table 2 ). The methylation levels of LINE-1 in the NTD samples were significantly lower than that in the control samples (54.57% compared with 59.03%, P , 0.001). LINE-1 also had the lowest methylation level in the cephalic malformation samples. Analyzed by one-factor analysis of variance, the difference in methylation levels between cephalic malformation, spina bifida, and control samples was significant (52.43%, 57.32%, and 59.03%, respectively; P , 0.001). This result prompted us to compare the methylation levels between 2 NTD subgroups (cephalic malformations and spina bifida) and control groups. Our data show a striking reduction in the methylation level of LINE-1 in the cephalic malformation group (P , 0.001), whereas there was no significant difference between the spina bifida and control groups (P = 0.15).
The methylation levels of every CpG site within LINE-1 were also evaluated. As shown in Figure 2 , methylation levels varied at the different CpG sites, the lowest level being located on the 5th CpG site (29.84%), whereas the 11th and 12th CpG sites at the 5# end had the highest methylation levels (85.88%). Taken together, compared with control samples, the methylation levels of all CpG sites in cephalic malformations were significantly lower (P , 0.001), whereas no significant differences were found in the spina bifida samples (P . 0.05).
Methylation levels were also compared according to sex in 48 NTD and 49 control samples. Apart from one sample (for which the sex could not be determined), the methylation levels of genomic DNA and LINE-1 elements did not statistically differ in males and females (see Table S1 under "Supplemental data" in the online issue).
To verify the methylation patterns within LINE-1, we took the same samples and analyzed their methylation status by using sodium-bisulfite modification followed by sequencing of the PCR products. Ten samples (including 3 controls and 7 NTD cases) were selected randomly for validation by bisulfite sequencing, and the data were analyzed by using a repeated-measures analysis. As shown in Figure 3 , the percentage of 5-methylated cytosine (5mC) in LINE-1 did not vary significantly within individuals (mean difference = 0.28%, P = 0.857) by using either method.
Correlation between global and LINE-1 methylation levels
Human repetitive elements have been used to estimate the level of genomic methylation in some cancers (16) (17) (18) (19) . Our results show a reduction in global and LINE-1 methylation levels in NTDs. However, unlike in cancer, we found no correlation between global methylation and the mean methylation levels of LINE-1. Interestingly, when the promoter area of LINE-1 was fragmented according to the location of the CpG sites, a significant correlation in the methylation levels was seen between LINE-1 and genomic DNA. As shown in Figure 4 , the methylation levels at the 5# end of the LINE-1 promoter, which include the 6th-12th CpG sites had a notable correlation with the global methylation levels. The correlation ratios for each CpG unit were 0.237 (P , 0.05), 0.276 (P , 0.01), and 0.240 (P , 0.05), respectively. No significant correlation was found between the 3# end of the LINE-1 promoter area (1st-5th CpG sites) and global methylation levels.
Assessment of risk of developing NTDs
In an attempt to develop a model for assessing the risk of developing NTDs on the basis of the methylation levels of genomic DNA and LINE-1, NTD samples were categorized FIGURE 2. Mean methylation levels of CpG sites in long interspersed nucleotide element-1 (LINE-1). Methylation levels of all CpG sites in LINE-1 were compared between samples from subjects with cephalic malformations or spina bifida and control subjects. CpG sites were numbered 1-12 from the 3# end to the 5# end in the promoter area of LINE-1. * , **Student's t test was performed: *P , 0.05, **P , 0.001 (relative to the respective control). n control = 49, n spina bifida = 21, and n cephalic malformation = 27. according to the quartile of methylation level found in the control samples. On the basis of the LINE-1 methylation level, 65% of NTD samples were grouped into the lowest quartile (methylation level 57.94%). Only 5 NTD samples (10.4%) were grouped into the highest quartile (methylation level 60.94%). Similarly, on the basis of global methylation levels, 44% of NTD samples were grouped into the lowest quartile (methylation level 4.19%), and 17.8% of NTD samples were grouped into the highest quartile (methylation level 6.84%). As shown in Table 3 , low LINE-1 methylation levels increased the risk of NTDs '5-fold (OR: 5.246; 95% CI: 1.519, 18.124) compared with high methylation levels. Because methylation patterns change throughout embryonic development, the OR was adjusted for gestation time and sex. After adjusting the OR to take into account gestation time and sex, the risk of NTDs associated with low LINE-1 methylation levels increased (AOR: 5.966; 95% CI: 1.568, 22.704). However, lower methylation levels of genomic DNA did not statistically confer a higher risk of NTDs (OR: 2.500; 95% CI: 0.812, 7.692), even after adjustment for gestation time and sex (AOR: 2.931; 95% CI: 0.870, 9.872).
Correlation between methylation levels found in fetal nervous tissue and maternal plasma nutrition
To investigate the possible relation between maternal nutrition and methylation status in matched offspring, we measured the concentrations of folic acid, vitamin B-12, and tHcy in maternal plasma. As shown in Table 4 , the mean concentration of plasma vitamin B-12 from NTD-affected subjects was significantly lower than that in the control group (70.16 pmol/L compared with 88.62 pmol/L, P , 0.05). Compared with the control samples, patient samples tended to have higher mean tHcy concentrations, but the difference was not significant (P = 0.068). No significant difference in concentrations of plasma folic acid was found in the patient samples compared with the control samples (P = 0.172).
We analyzed the underlying relation between the methylation levels in offspring and maternal plasma nutrition (see Table S2 under "Supplemental data" in the online issue). No significant correlation was found between global methylation levels and maternal plasma concentrations of folate, vitamin B-12, or homocysteine. There was also no correlation between hypomethylation of the CpG sites in LINE-1 and maternal nutrition.
DISCUSSION
Aberrations in genome-wide methylation during embryogenesis have been consistently linked to developmental abnormalities at birth (22) . Several reports (23) (24) (25) showed that inhibition of the methylation cycle induced a high frequency of cranial NTDs in cultured mouse and chick embryos. This suggests that aberrant genomic methylation underlies the complex pathogenesis of NTDs. In the current study, we found that global methylation levels were significantly lower in neural tissues of clinical NTD case subjects, showing that an impaired DNA methylation pattern is also present in clinical NTD subjects. Because DNA hypomethylation functions to increase recombination and/or hamper chromosomal segregation during mitosis (26) , along with the fact that '80% of embryos with NTDs who survived up to 9 wk all had concurrent chromosomal abnormalities (especially trisomy) (27) , the genome-wide hypomethylation found in our study may play a role in the development of chromosome abnormalities in NTDs, which may shed some light on the mechanisms involved in the cause of NTDs.
Hypomethylation of LINE-1 in some cancers is thought to be connected to genomic instability and endogenous DNA doublestrand breaks, resulting in a surrogate marker being expressed by tumors (26, (28) (29) (30) . These reports (26, (28) (29) (30) led us to investigate the possibility that these LINE-1 methylation patterns may not be restricted to cancerous cells but may also be present during embryonic development. In the current study, we found significant hypomethylation of LINE-1 in NTDs. In particular, this reduction in LINE-1 methylation was accompanied by an increased risk of NTDs, indicating that LINE-1 hypomethylation is likely to contribute to the development of NTDs. Demethylation in the LINE-1 promoter region leads to increased levels of LINE-1 transcription (31, 32), causing cellular apoptosis (33, 34) . Therefore, the hypomethylation of CpG sites within the LINE-1 FIGURE 4. Correlation of global methylation level and CpG-unit methylation levels in long interspersed nucleotide element-1 (LINE-1). Bivariate correlation was performed. CpG sites were numbered 1-12 from the 3# end to the 5# end in the promoter area of LINE-1. n case :n control = 45: 49. promoter region that we found in the current study may imply an increase in retrotransposition and, thus, decreased chromosomal stability in NTD case subjects during early embryonic development. Further study of LINE-1 hypomethylation is needed to clarify its role in facilitating chromosomal instability and retrotransposition.
The clinical types of NTDs differ depending on the site at which closure fails. The failure of closure 2 is responsible for the maldevelopment of the forebrain and anterior midbrain, resulting in more severe clinical outcomes, such as anencephaly (35, 36) . It is notable that global methylation levels and LINE-1 methylation levels were reduced significantly in the cephalic malformation subgroup compared with the levels in the spina bifida subgroup. Because most cephalic malformations selected for our study were anencephalus NTDs, the strikingly decreased methylation level in the cephalic malformation subgroup may lend support to the concept that anencephaly and spina bifida may be etiologically heterogeneous, especially pertaining to the role of methylation modification, which is affected by folate metabolism. Such an assumption is further supported by a study (37) that showed that the prevalence of anencephaly in the United States declined significantly, compared with that of spina bifida, after mandatory folic acid fortification. Nevertheless, the decreased levels of genome-wide and LINE-1 methylation in NTDs, particularly in the cephalic malformation subgroup, were consistent with the hypothesis that methylation and demethylation during embryogenesis are associated with the progress of neural tube closure.
It is widely accepted that the establishment and maintenance of methylation patterns in global genomic DNA, especially those of transposons and imprinted genes, are influenced by early nutrition (11, (38) (39) (40) (41) (42) (43) , and folate-related one-carbon metabolism plays a key role in these reactions. In our study, significantly reduced maternal plasma vitamin B-12 concentrations were observed in NTD case samples compared with control samples, along with a trend of lower plasma concentrations of folate and higher concentrations of tHcy. There appears to be 2 possible mechanisms by which folic acid deficiency may increase the risk of NTDs: 1) by inducing an imbalance in DNA synthesis and repair or 2) by altering normal DNA methylation. Cohort studies suggested an inverse correlation between cord plasma homocysteine and LINE-1 methylation (44), and lower folate intakes would more likely lead to the development of LINE-1 hypomethylation colon cancers (20) . In our study, the findings of genome-wide demethylation, as well as the reduction of LINE-1 methylation levels in the neural tissues of NTD samples, coupled with changes in the maternal functional shortage of folate and vitamin B-12, strongly indicate that disturbed one-carbon unit metabolism could have a deleterious effect on DNA methylation during pregnancy. The lack of a significant correlation between LINE-1 methylation levels and global methylation levels and maternal folate, vitamin B-12, and tHcy concentrations in this study may be explained by the consistently poor plasma levels of folate and vitamin B-12 in the case and control groups in this area. Our results were obtained from the analysis of subjects living in a rural mountain area, where poor nutrition conditions are common in the general population but are more significant in some mothers with NTD offsprings because of geographic and sociodemographic reasons (45, 46) . Long-term conditions of nutrition deficiency may not only interfere with DNA methylation but also other one-carbon metabolisms and genetic polymorphisms, which are known to increase the risk of NTDs (8, (47) (48) (49) (50) . On the other hand, the characteristic dispersion of LINE-1 elements throughout the genome in the form of methylation heterogeneities within various loci also promote further research into understanding whether each LINE-1 locus possesses a distinct methylation pattern depending on cell type or location. Nevertheless, the joint measurements of NTDs, LINE-1 methylation status, and maternal one-carbon unit micronutrient levels could be of clinical significance in understanding and further evaluating the risk of NTDs or other congenital abnormalities.
LINE-1 methylation levels could be a potential indicator of global DNA methylation, especially in cancer cell lines (16) . A significant correlation was seen between the methylation levels in genomic DNA and the 5# end of the LINE-1 promoter region in the neural tissue samples. This suggests that the 5# end of the LINE-1 promoter may be a methylation marker for genomic DNA. Our data suggest that global hypomethylation is associated with the methylation status of LINE-1 during embryogenesis. Therefore, it is tempting to speculate that hypomethylation of LINE-1 may be an epigenetic marker during embryonic development.
In conclusion, hypomethylation of genomic DNA and LINE-1 is one of the possible epigenetic variations associated with the complex etiology of NTDs. Lower LINE-1 methylation levels are potentially related to an increased risk of NTDs. Lower maternal plasma concentrations of folate and vitamin B-12, coupled with higher concentrations of homocysteine, are present in NTDaffected mothers. Our data provide evidence supporting the relation between disturbed one-carbon unit metabolism and NTD incidence, implying that improvements in nutrition during early pregnancy may prevent NTDs, possibly via the donation of methyl groups important for embryo development.
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